Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Veracyte sells genomic tests that help doctors diagnose cancer more accurately and avoid unnecessary surgeries.
Veracyte is a diagnostics company that sells lab tests which help doctors figure out whether a suspicious lump or nodule is actually cancer. Its best-known test, Afirma, looks at genetic material from a thyroid nodule to tell whether it is benign, so many patients can skip surgery to remove the gland. That matters because thyroid nodules are extremely common, but only a small share turn out to be cancerous, and removing a thyroid for life comes with real costs.
The business runs on a simple loop: a doctor orders a test, a sample is sent to Veracyte's lab, and the company performs the genomic analysis and bills for it. Veracyte does not sell machines to hospitals; it sells answers, paid for mostly by insurers and patients. Its edge comes from proprietary gene-expression data and clinical studies showing its tests change decisions — that evidence is what convinces payers to cover the tests and doctors to trust them. The company has widened beyond thyroid into tests for prostate cancer, breast cancer, and lung cancer, largely through acquisitions, so it is no longer a one-test story. That expansion is both the opportunity and the risk. Each new market means competing with larger diagnostic players and lab giants, and winning insurance coverage test by test takes time and money. Veracyte also spends heavily on research and sales, which can keep profits thin even as revenue grows. It has been building toward profitability rather than paying dividends, and it has used its cash to buy its way into new cancer types instead of inventing every test from scratch.
The interesting history: the company began life as Calderome, a shell-like leftover, before becoming Veracyte. Its Afirma test was one of the first widely adopted genomic tests in thyroid care, and that success funded the push into other cancers. Today the question investors wrestle with is whether Veracyte can repeat that playbook — strong evidence, payer coverage, doctor adoption — across several cancer types at once, and eventually turn a fast-growing testing business into a durable, profitable one.
Saved answer · last researched 15 Nov 2026